Airborne and potentially deadly, the virus that causes COVID-19 can only be studied safely under high-level biosafety conditions. Scientists handling the infectious virus must wear full-body biohazard suits with pressurized ...
Jul 21, 2020
0
5
Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, ...
Mar 19, 2012
0
0
(Medical Xpress)—Yale researchers eradicated most melanoma tumors by exposing them to a fast-acting virus, they report in the June 15 edition of the Journal of Virology.
Jun 17, 2013
0
0
National Institutes of Health (NIH) scientists report that a single dose of an experimental Ebola virus (EBOV) vaccine completely protects cynomolgus macaques against the current EBOV outbreak strain, EBOV-Makona, when given ...
Aug 6, 2015
0
59
An experimental vaccine is effective at preventing pneumonia in mice infected with the COVID-19 virus, according to a study from Washington University School of Medicine in St. Louis. The vaccine, which is made from a mild ...
Aug 12, 2020
0
103
(Medical Xpress)—Scientists at Emory Vaccine Center have shown that an immune regulatory molecule called IL-21 is needed for long-lasting antibody responses in mice against viral infections.
May 23, 2013
0
0
Almost as quickly as SARS-CoV-2 turned the world on its head, the spike protein studding its surface became a molecular celebrity. It is the virus's key to our cells, hence a critical target: Many promising treatments and ...
Aug 11, 2020
0
7
(Medical Xpress)—A brain-computer-interphase that is optogenetically-enabled is one of the most fantastic technologies we might envision today. It is likely that its full power could only be realized under the guidance ...
Viruses and their hosts are in a eternal game of one-upmanship. If a host cell evolves a way to stop a virus from spreading, the virus will look for a new path. And so on and so forth.
Jan 11, 2017
0
20
A phase 1 randomized controlled trial has found an Ebola virus disease (EVD) vaccine, developed in Canada, was well-tolerated with no safety concerns, and high antibodies were present in participants 6 months after immunization. ...
Jun 19, 2017
0
105
